Pharmacyclics, Inc. (PCYC) recently announced the enrollment of the fifth patient in a phase III study, RESONATE-2, which is being conducted to evaluate ibrutinib as a monotherapy versus...(read more
Pharmacyclics, Inc. (PCYC) recently announced the enrollment of the fifth patient in a phase II study that is being conducted with ibrutinib in patients suffering from relapsed or refractory...(read more
The market was quite ugly on Tuesday. However, there are some stocks still acting well, or consolidating bullishly, so we’re going to take a look at the long side. They’re getting oversold so there may be some sort of snapback in the...